MX2019005933A - Polipeptidos biespecificos para gitr y ctla-4. - Google Patents

Polipeptidos biespecificos para gitr y ctla-4.

Info

Publication number
MX2019005933A
MX2019005933A MX2019005933A MX2019005933A MX2019005933A MX 2019005933 A MX2019005933 A MX 2019005933A MX 2019005933 A MX2019005933 A MX 2019005933A MX 2019005933 A MX2019005933 A MX 2019005933A MX 2019005933 A MX2019005933 A MX 2019005933A
Authority
MX
Mexico
Prior art keywords
gitr
ctla
bispecific polypeptides
polypeptides
bispecific
Prior art date
Application number
MX2019005933A
Other languages
English (en)
Inventor
Ellmark Peter
Furebring Christina
Fritzell Sara
VEITONMÄKI Niina
NORLÉN Per
Kvarnhammar Anne
Levin Mattias
Nyblom Eva
WINNERSTAM Magnus
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of MX2019005933A publication Critical patent/MX2019005933A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención proporciona polipéptidos multiespecíficos, tales como anticuerpos biespecíficos, que comprenden un primer dominio de fijación capaz de fijarse específicamente a GITR, y un segundo dominio de fijación, capaz de fijarse específicamente a CTLA-4. La invención proporciona además composiciones de dichos polipéptidos biespecíficos, así como métodos y usos de estos.
MX2019005933A 2016-11-21 2017-11-21 Polipeptidos biespecificos para gitr y ctla-4. MX2019005933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619652.9A GB201619652D0 (en) 2016-11-21 2016-11-21 Novel polypeptides
PCT/EP2017/079925 WO2018091739A1 (en) 2016-11-21 2017-11-21 Bispecific polypeptides to gitr and ctla-4

Publications (1)

Publication Number Publication Date
MX2019005933A true MX2019005933A (es) 2019-07-08

Family

ID=57993718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005933A MX2019005933A (es) 2016-11-21 2017-11-21 Polipeptidos biespecificos para gitr y ctla-4.

Country Status (13)

Country Link
US (1) US20190309084A1 (es)
EP (1) EP3541475A1 (es)
JP (1) JP2019535282A (es)
KR (1) KR20190082235A (es)
CN (1) CN109963621A (es)
AU (1) AU2017360093A1 (es)
BR (1) BR112019010139A2 (es)
CA (1) CA3044345A1 (es)
GB (1) GB201619652D0 (es)
IL (1) IL266765A (es)
MX (1) MX2019005933A (es)
RU (1) RU2019116638A (es)
WO (1) WO2018091739A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11421029B2 (en) * 2017-09-01 2022-08-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recombinant bispecific antibodies to PD-L1 and CTLA-4
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG-BINDING MOLECULES
EP3831849A1 (en) * 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2779559A1 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution Inc. Variant fc regions
US9212230B2 (en) 2007-03-29 2015-12-15 Genmab A/S Bispecific antibodies and methods for production thereof
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
DK3151921T3 (da) * 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
LT3221346T (lt) * 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
CN105669867A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗gitr/ctla-4双特异性抗体及其制备方法和用途
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores

Also Published As

Publication number Publication date
AU2017360093A1 (en) 2019-06-20
GB201619652D0 (en) 2017-01-04
EP3541475A1 (en) 2019-09-25
CA3044345A1 (en) 2018-05-24
KR20190082235A (ko) 2019-07-09
US20190309084A1 (en) 2019-10-10
JP2019535282A (ja) 2019-12-12
WO2018091739A1 (en) 2018-05-24
RU2019116638A (ru) 2020-12-21
BR112019010139A2 (pt) 2019-10-08
IL266765A (en) 2019-07-31
CN109963621A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12019502283A1 (en) Anti-lag3 antibodies
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2018016364A (es) Anticuerpos anti-pd-l1.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2017014699A (es) Polipeptidos novedosos.
MY191581A (en) Anti-pd-1 antibodies
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
NZ725568A (en) Modified j-chain
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
PH12017502277A1 (en) Multi-specific binding proteins